Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide [Seeking Alpha]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Seeking Alpha
Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » adventtr/iStock via Getty Images The last time I wrote about Nurix Therapeutics, Inc. ( NRIX ) it was in a Seeking Alpha article entitled " Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones ." With respect to this More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Cent
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29 [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics (NRIX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Nurix Therapeutics (NRIX) had its price target lowered by Wells Fargo & Company from $29.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics (NRIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire
NRIX
Earnings
- 1/28/26 - Beat
NRIX
Sec Filings
- 4/8/26 - Form 10-Q
- 4/8/26 - Form 8-K
- 4/2/26 - Form 4
- NRIX's page on the SEC website